院外心脏骤停心室颤动波形特征与心血管药物使用的关系
该研究纳入荷兰院外心脏骤停注册研究中990例心室颤动患者,分析心血管药物使用与AMSA的关联,并在多变量线性回归中校正心血管疾病、心血管疾病危险因素及院外心脏骤停特征。校正后仅保钾药物与较低的AMSA相关(OR 0.46,95%CI 0.10-0.81,P<0.012)。药物使用仅能解释AMSA变异的很小部分(R方0.003-0.026),加入院外心脏骤停特征后R方变化最大(0.09-0.15)。作者认为心血管药物对AMSA不大可能有强而具临床相关性的独立药理作用。
要点
- 990例心室颤动院外心脏骤停患者中,校正心血管疾病、危险因素及院外心脏骤停特征后,仅保钾药物与较低AMSA相关(OR 0.46,95%CI 0.10-0.81,P<0.012)。
- 药物使用仅解释AMSA变异的很小部分(R方0.003-0.026),加入院外心脏骤停特征后R方变化最大(0.09-0.15)。
- 有无心血管药物使用患者中,AMSA随急救呼叫至心电图延迟增加而下降的幅度相同(均P>0.05)。
- 作者认为AMSA或许可在不考虑心血管药物使用的情况下用作院外心脏骤停患者管理工具。
适用人群与场景
- 荷兰院外心脏骤停注册研究中990例心室颤动患者,且具有病史和心血管药物使用信息。
研究设计与关键结果
- 多变量线性回归模型校正心血管疾病、心血管疾病危险因素及院外心脏骤停特征后,与使用其他心血管药物的患者相比,仅保钾药物与较低AMSA相关(OR 0.46,95%CI 0.10-0.81,P<0.012)。
- 有无心血管药物使用患者中,AMSA随急救呼叫至心电图延迟增加而下降的幅度相同(均P>0.05)。
- 药物使用仅解释AMSA变异的很小部分(R方0.003-0.026);加入院外心脏骤停特征后R方变化最大(0.09-0.15)。
证据类型、等级与局限
- 观察性研究:基于荷兰院外心脏骤停注册研究的990例心室颤动患者,采用多变量线性回归分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,心血管药物对AMSA不大可能有强而具临床相关性的独立药理作用,AMSA或许可在不考虑心血管药物使用的情况下用作院外心脏骤停患者管理工具。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ventricular fibrillation (VF) waveform analyses are considered a reliable proxy for OHCA characteristics in out-of-hospital cardiac arrest (OHCA), but patient characteristics such as cardiovascular medication use might also be associated with changes in VF waveform measures.
OBJECTIVES: To assess associations between cardiovascular medication use and amplitude spectrum area (AMSA) of VF, while correcting for the presence of cardiovascular disease (CVD), CVD risk factors, and OHCA characteristics.
METHODS: We included 990 VF patients from an OHCA registry in the Netherlands, with available information on medical history and cardiovascular medication use. Associations between cardiovascular medication use and AMSA were tested in a multivariate linear regression model, adjusting for CVD, CVD risk factors, and OHCA characteristics. Model performance was shown using R-square and R-change. We also calculated whether medication use was associated with faster dissolution of AMSA to lower values with increasing time delay.
RESULTS: In the multivariate analysis, when corrected for CVD, CVD risk factors and OHCA characteristics, only potassium-sparing agents were associated with a lower AMSA when compared to patients using other cardiovascular medications (OR 0.46 [95% CI 0.10-0.81]; P < 0.012). The decrease in AMSA with increasing EMS-call-to-ECG delay was the same for patients with and without cardiovascular medication use (all P > 0.05). Only a small part of the variance in AMSA could be explained by medication use (R-square 0.003- 0.026). Adding OHCA characteristics to the model resulted in the largest R square change (0.09-0.15).
CONCLUSIONS: It is unlikely that there is a strong and clinically relevant independent pharmacologic effect of cardiovascular medication use on AMSA. In OHCA, AMSA might be used as patient management tool without considering cardiovascular medication use.
参考来源
- Hulleman M, Salcido DD, Menegazzi JJ, et al. Ventricular fibrillation waveform characteristics in out-of-hospital cardiac arrest and cardiovascular medication use. Resuscitation. 2020. PMID: 32169604. doi:10.1016/j.resuscitation.2020.02.027
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。